93 unknown. 93 Phase 2, 11 Phase 1, 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 93 | Unknown 93 |
| Phase 1 | 11 | Unknown 11 |
| Phase 3 | 7 | Unknown 7 |
Follow Chemotherapy: new trials by email Literature Review of Chemotherapy trials Research Report on Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer Stereotactic body radiation, Nimotuzumab, mono-chemotherapy - Advanced Pancreatic Cancer | Phase 2 | Unknown | Peking University Third Hospital | 73 | 2024-06-01 | 2024-05-20 |
| Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer Metformin, Radiotherapy, Chemotherapy - Cervical Cancer, Radiotherapy | Phase 2 | Unknown | Peking Union Medical College Hospital | 51 | 2024-04-15 | 2025-01-14 |
| Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) Camrelizumab, Thalidomide 50mg, Thalidomide 100mg - Lung Cancer, Nonsmall Cell, Esophageal Carcinoma | Phase 2 | Unknown | Henan Cancer Hospital | 132 | 2024-01-19 | 2024-03-29 |
| A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma Surufatinib plus chemotherapy, Chemotherapy - Osteosarcoma | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 160 | 2024-01-09 | 2024-04-17 |
| Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence SBRT, Chemotherapy, PD-1 antibody - Radiotherapy, Immunotherapy | Phase 2 | Unknown | Fudan University | 80 | 2023-09-25 | 2023-11-07 |
| Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement Orelabrutinib, Rituximab, Chemotherapy - CNS Lymphoma | Phase 2 | Unknown | Ruijin Hospital | 25 | 2023-08-10 | 2023-09-05 |
| Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer GLS-012+GLS-010, GLS-012+GLS-010+pemetrexed+carboplatin, GLS-012+GLS-010+paclitaxel+carboplatin - Advanced Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | Guangzhou Gloria Biosciences Co., Ltd. | 152 | 2023-08-10 | 2023-08-07 |
| Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma Camrelizumab, Cisplatin, Carboplatin - Head and Neck Squamous Cell Carcinoma | Phase 2 | Unknown | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 46 | 2023-03-01 | 2023-12-20 |
| Durvalumab and Lenvatinib With or Without Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer Durvalumab, Lenvatinib Oral Product, Chemotherapy - Biliary Tract Neoplasms, Immunotherapy | Phase 2 | Unknown | Peking Union Medical College Hospital | 40 | 2022-12-14 | 2023-11-15 |
| Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC HLX07, HLX10, placebo - Nasopharyngeal Carcinoma by AJCC V8 Stage | Phase 2 | Unknown | Shanghai Henlius Biotech | 75 | 2022-12-14 | 2024-06-17 |
| Addition of Everolimus to Standard of Care in Carcinoma Gallbladder Everolimus 10 mg, Standard of care - Gallbladder Cancer | Phase 2 / Phase 3 | Unknown | Banaras Hindu University | 56 | 2022-11-01 | 2024-08-13 |
| Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer Envafolimab, Lenvatinib, VP-16 - Ovarian Cancer, Epithelial | Phase 2 | Unknown | Zhongda Hospital | 20 | 2022-06-30 | 2022-06-16 |
| A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC envafolimab - Non-small Cell Lung Cancer | Phase 2 | Unknown | Second Xiangya Hospital of Central South University | 42 | 2022-05-15 | 2022-05-04 |
| Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC endoscopic surgery - Recurrent Nasopharyngeal Carcinoma | Phase 2 | Unknown | Eye & ENT Hospital of Fudan University | 77 | 2022-05-08 | 2022-05-10 |
| WX-0593 Combined With Concurrent Chemoradiotherapy in Unresectable Locally Advanced NSCLC WX-0593 Tablets, chemotherapy, Thoracic Radiation Therapy（TRT） - Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Unknown | Jinming Yu | 40 | 2022-04-30 | 2022-04-28 |
| Envafolimab Combined With Endostar and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Envafolimab, Endostar, Nab paclitaxel - Advanced Pancreatic Cancer | Phase 2 | Unknown | The Affiliated Hospital of Xuzhou Medical University | 20 | 2022-04-01 | 2022-03-28 |
| Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma Envafolimab, Oxaliplatin, S1 - Metastatic or Recurrent Gastric Adenocarcinoma | Phase 2 | Unknown | Liangjun Zhu M.M. | 38 | 2022-03-01 | 2024-01-05 |
| Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC Chemotherapy, Alflutinib plus chemotherapy - NSCLC | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital of Henan University of Science and Technology | 90 | 2022-03-01 | 2022-01-26 |
| A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer Radiotherapy group, Camrelizumab, Chemotherapy - Esophageal Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 118 | 2021-12-31 | 2022-01-11 |
| A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer Bevacizumab, chemotherapy, Fluzoparib - Ovarian Cancer | Phase 2 | Unknown | The Second Affiliated Hospital of Shandong First Medical University | 60 | 2021-12-24 | 2021-12-28 |
Showing 20 of 93. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (15) · Breast Neoplasms (7) · Stomach Neoplasms (6) · Colorectal Neoplasms (5) · Neoplasms (5) · Rectal Neoplasms (5) · Esophageal Squamous Cell Carcinoma (4) · Lung Neoplasms (4) · Nasopharyngeal Carcinoma (4) · Osteosarcoma (4) · Pancreatic Neoplasms (4) · Esophageal Neoplasms (3) · Neoplasm Metastasis (3) · Biliary Tract Neoplasms (2) · Brain Neoplasms (2)
Sun Yat-sen University (4) · Eye & ENT Hospital of Fudan University (3) · Fudan University (3) · Peking Union Medical College Hospital (3) · Ruijin Hospital (3) · Zhejiang Cancer Hospital (3) · Beni-Suef University (2) · Betta Pharmaceuticals Co., Ltd. (2) · Chinese PLA General Hospital (2) · Ningbo Cancer Hospital (2) · Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Shanghai International Medical Center (2) · Shenzhen Hornetcorn Bio-technology Company, LTD (2) · Sichuan Cancer Hospital and Research Institute (2) · Academic Emergency County Hospital Sibiu (1)
China (60) · Italy (4) · Egypt (3) · France (3) · South Korea (3) · United States (3) · Israel (2) · Brazil (1) · Germany (1) · India (1) · Puerto Rico (1) · Romania (1) · Russia (1) · Saudi Arabia (1) · Singapore (1)
Hongmeng Yu, MD,PHD (3) · Huajun Jin (2) · Jiangtao Wang (2) · Qijun Qian (2) · Ahmed A El Berry, Ph.D. (1) · Ahmed Abdullah Elberry Elberry, MD (1) · Alexey Tryakin, MD, PhD (1) · Amr Shafik Tawfik, MD (1) · Ben Chue, MD (1) · Birendra K Sah, PH D (1) · Chen Li, PH D (1) · Chunji Gao, Professor (1) · Cihan Gani, Dr. (1) · Dazhi Xu, PHD (1)
PMID 10655437, PMID 11937316, PMID 12177103, PMID 12434281, PMID 14506149, PMID 16011702, PMID 16078267, PMID 16265674, PMID 16510333, PMID 16598416, PMID 16645718, PMID 17544337, PMID 17647306, PMID 17909941, PMID 18217208, PMID 18577561, PMID 18990510, PMID 19147777, PMID 19957326, PMID 19985059, PMID 20694800, PMID 20708924, PMID 20921456, PMID 20974795, PMID 21087935, PMID 21171927, PMID 21292687, PMID 21297126, PMID 21297433, PMID 21327862, PMID 22132908, PMID 22331797, PMID 22747087, PMID 22747092, PMID 23043252, PMID 23092726, PMID 23536435, PMID 23813229, PMID 24560760, PMID 24626721, PMID 24696052, PMID 24847085, PMID 24903904, PMID 25542058, PMID 27197987, PMID 33559053, PMID 37185961, PMID 39756446, PMID 40347958, PMID 40638104
2015 (1), 2016 (1)